The effect of intratumoral recombinant interferon y (rIFN-y) as adjuvant to open cytoreduction and external irradiation of 60 Gy on survival in adults with a newly diagnosed high-grade cerebral glioma was studied. The patients were randomised during surgery into the rIFN-y group (n = 14) or the control group (n = 17), and the latter received a subcutaneous reservoir of rIFN-7 injections. Intratumoral rIFN-y was given three times a week for 4 weeks until radiotherapy, escalating the dose from 5 gig to 50;Lg. Both groups received external whole-brain irradiation of 40 Gy and a local boost of 20 Gy. After radiotherapy, rIFN-y was continued with 50 iLg twice a week up to 9 weeks. The patients received no chemotherapy. Intratumoral rIFN-7 was tolerated well with transient fever only. There were 12 glioblastomas (GBs) in the control group and nine in the rIFN-7 group with completed irradiation. The patients were followed clinically and by computerised tomography (CT) every third month until death. Tumour responses were seen in three interferon-treated (one still alive 45 months after operation) and in two conventionally treated patients. The progression of the tumour volumes on CT did not differ between the IFN-treated and control groups. There were no differences in the survival times. Median survival of the rIFN-^-treated patients was 54 weeks (95% CI 35-68) and of the control patients 55 weeks (95% CI 41-77). Intratumoral rIFN-y given in the study doses does not seem to inhibit tumour growth or improve the prognosis of patients with high-grade glioma.
Glioblastomas (GBs) make up 35-75% of all primary brain tumours (Kallio, 1988) . Glioblastoma multiforme and anaplastic astrocytoma are the most common and the most malignant. Malignant gliomas are treated surgically, usually with radiotherapy, and sometimes also with chemotherapy (Nazarro & Neuwelt, 1990) , and these treatments prolong the life of a patient but practically never completely eradicate the tumour. Since the beginning of 1980s, interferons (IFNs) have been used to treat malignant gliomas. Mainly m (IFN-a) and P (IFN-P) have been tried (Nagai & Arai, 1982; Takakura, 1987; Allen et al., 1991; Yung et al., 1991) . Promising results have also been reported with -y-interferon (IFN-y) (Mahaley et al., 1983) .
Gliomas are immunosuppressive, and the defect is at least partially attributable to impaired T-cell function (Roszman et al., 1991) . The rationale of rIFN-7 treatment of glioma is to restore and enhance the local immune response against glioma tissue by up-regulation of glioma-associated and MHC antigens, and by recruitment and activation of leucocytes. IFN-y may act antiproliferatively by unmasking antigenic determinants on the glioma cells and by inducing expression of receptors for tumour necrosis factor (TNF) on cells specific for IFN-y (Woll & Crowther, 1991) . rIFN-7 was chosen for clinical study because IFN-'y is the strongest inducer of la antigen, especially class II antigens (DRA antigens), expression and is also less neurotoxic than IFN-e or IFN-P, making high intracerebral doses possible. In addition, glioma patients may have reduced IFN-y production as a result of reduced T-lymphocyte activity. This is of specific importance as IFN-y is a potent activator of macrophages, and the production of IFN-y is influenced by interleukin 2 (IL-2) (Lee & Bigner, 1985) . In order to achieve sufficiently high concentrations of rIFN-y in the tumour, rIFN-y was administered locally into the tumour cavity.
In the present study rIFN-y Tumour responses were considered complete if the volume of the tumour did not increase at all, and partial if the increase in volume was no greater than 25% in 6 months.
Statistical analysis
The cumulative survivals were computed using the productlimit method, and the difference between the survivals of the two groups was evaluated with the generalised Wilcoxon test using the BMDP statistical software (Benedetti, 1990) . The confidence intervals (95% CI) for the median survivals were calculated according to Brookmeyer and Crowley (1982 Twnour response to post-radiotherapy rIFN-y After radiotherapy some tumour responses were seen. One rIFN-^-treated patient is still alive 45 months after the operation with complete tumour response until a recently detected small recurrence (Figure 2 ). In two of eight patients receiving the whole planed dose of rIFN-y the tumour volumes were reduced after the rIFN-y treatment period, in one patient for 7 months and in the other one for 41 months. In the control group the volume remained stable in three patients. In the other patients the tumour grew relentlessly in spite of all treatments. In the valid rIFN-group (n= 8) there were two complete and one prtial responses (3/8). In the valid conventional treatment group (n = 14), two complete responses were seen, giving response rates of 37.5% and 14.3%. The difference is not statistically significant.
Survival analysis
The median survival of all the patients was 46 weeks (95% CI 35-55), but one patient is still alive 45 months after operation. The median survivals of the rIFN-^-treated and conventionally treated groups were 41 (95% CI 12-55) weeks and 52 (95% CI 31-60) weeks, respectively, for all patients (Figure 2) , the difference being not statistically significant (P = 91). When analysing the survival of patients who received the whole planned treatments, the valid study groups, the median survival was 54 (95% CI 35-68) weeks for the conventional group and 55 (95% CI 41-77) weeks for the rIFN--group. The total rIFN-y dose was 1.09-1.55 mg. There was no significant difference (P = 0.35) in the survival times of these groups either. When only the glioblas- (Winger et al., 1989) . This was a rIFN-y dose-defining study, and tumour responses were looked for; tumour responses were seen in both groups, and the tumour volume changes gave the impression that increase in tumour growth took place after rIFN-y injections were ceased. With a patient population of 31 at the 5% significance level and 80% power level only 25% or greater differences in 1 year survival rates could have been detected (Machin & Campbell, 1987) . As a consequence we feel that, although small, our study did not miss clinically truly relevant differences. Intratumoral rIFN-y treatment in glioblastoma patients does not seem to improve the survival of the patients, at least not with the low doses used here. The median survival of our rIFN-y-treated patients, 46 weeks from operation, is similar to that reported in literature (Deutsch et al., 1989; Shapiro et al., 1992) . The patient population is representative of that generally participating in clinical studies, and randomisation succeeded rather well. There were no differences in the survival of the rIFN-y-treated and conventionally treated patients. However, the only long-term survivor did belong to the rIFN--y group.
Conclusions
Administration of rIFN-y into the cavity of cerebral glioma is safe and well tolerated. There is no evidence that we achieved the desired immunomodulation in the tumours and the adjacent brain tissue. With the present dosage and administration rIFN--y does not seem to increase survival time in cerebral glioblastoma of adults. Whether higher doses and longer administration would make a difference remains to be determined. rIFN-y may have a role as adjuvant to other antineoplastic agents in the treatment of glioma.
